Department of Comprehensive Oncology;
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital;
Chinese Academy of Medical Sciences and Peking Union Medical College;
Department of Medical Oncology;
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital;
Chinese Academy of Medical Sciences and Peking Union Medical College;
ALK; crizotinib; non-small-cell; lung; cancer; resistance; sequential; therapy;